

# Cigarette Smoking, Alcohol Consumption, and the Risk of Systemic Lupus Erythematosus: A Case-Control Study

NAJEEB O. GHAUSSY, WILMER L. SIBBITT Jr, and CLIFFORD R. QUALLS

**ABSTRACT. Objective.** To investigate the effects of cigarette smoking and alcohol consumption on the development of systemic lupus erythematosus (SLE).

**Methods.** We interviewed 125 patients with SLE and 125 controls in a case-control study. Demographically similar controls randomly selected from outpatient clinics were matched to SLE cases for sex and age. Clinical data, including cigarette smoking, drinking habits, and other demographic variables, were collected by an interview-administered questionnaire.

**Results.** To minimize bias associated with reactive habits induced by disease, cigarette smoking before the diagnosis of SLE was the primary variable for subsequent analysis. Analysis of the data by multivariate conditional logistic regression revealed that both cigarette smoking before SLE diagnosis and ex-smoking before SLE diagnosis significantly increased the risk of development of SLE (OR 6.69, 95% CI 2.59, 17.28,  $p < 0.001$ ; and OR 3.62, 95% CI 1.22, 10.70,  $p = 0.02$ , respectively). This association remained even when statistically controlling for the effects of family history and education, indicating an independent effect. Alcohol did not place an individual at increased risk nor did it have a protective role.

**Conclusion.** The results of this study provide further evidence that cigarette smoking may be an associated risk factor for the development of SLE. (J Rheumatol 2001;28:2449–53)

## Key Indexing Terms:

SYSTEMIC LUPUS ERYTHEMATOSUS  
TOBACCO

ALCOHOL

CIGARETTE SMOKING  
EPIDEMIOLOGY

Genetics, sex, and hormonal status are major predisposing factors associated with the development of systemic lupus erythematosus (SLE)<sup>1-5</sup>. However, initiation of disease and variations in temporal activity are likely influenced by the environment and other exogenous factors<sup>6,7</sup>. That many monozygotic twins are discordant for SLE suggests that environmental and developmental factors play important roles in disease pathogenesis<sup>8-10</sup>. Environmental agents that have been implicated in the initiation and exacerbation of SLE include ultraviolet (UV) light<sup>11,12</sup>, viral infections<sup>13</sup>, and other exogenous factors<sup>14</sup>.

A few epidemiological studies have examined the possible association of smoking and SLE<sup>15-19</sup>. In 1993, Reidenberg, *et al* showed that slow acetylation phenotype and exposure to environmental amines are not principal causes of idiopathic SLE<sup>15</sup>. In regard to smoking, there were no differences in the smoking history between the SLE cases and the “friend” controls<sup>15</sup>. In 1995 Nagata, *et al* showed using self-administered questionnaires that current smoking had a significant increase in the risk of SLE<sup>16</sup>. In 1998 Hardy, *et al* also showed a significant increase in the risk of development of SLE in current smoking and concluded a significant positive association between SLE and smoking<sup>17</sup>. In the present study, the first in a predominantly Hispanic population, we further evaluate the association of cigarettes with SLE.

From the University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.

Supported by research grant RO1 NS 35708 from the National Institutes of Health.

N.O. Ghaussy, MD, Resident Physician, Department of Internal Medicine; W.L. Sibbitt Jr, MD, Professor of Internal Medicine and Neurology, Division of Rheumatology, Departments of Internal Medicine and Neurology, and Medical Research Director, Center for Clinical and Magnetic Resonance Research; C.R. Qualls, PhD, Professor of Mathematics and Statistics and Epidemiology, Departments of Mathematics and Statistics, and Epidemiology, Staff Statistician, Clinical Research Center.

Address reprint requests to Dr. W.L. Sibbitt Jr, Department of Internal Medicine, 5th floor ACC, University of New Mexico Health Sciences Center, Albuquerque, NM 87131.

Submitted November 8, 2000; revision accepted June 18, 2001.

## MATERIALS AND METHODS

**Subjects and study design.** A single interviewer collected epidemiological data for this study using a standard questionnaire form designed to record demographic details that included cigarette smoking, alcohol consumption, education, and income. This study was approved by the Institutional Review Board. All 137 patients with well characterized SLE from the University of New Mexico Systemic Lupus Data Base were interviewed by telephone, and the data were directly entered into the questionnaire form. The diagnosis of SLE was confirmed in each subject using the American Rheumatism Association 1982 and American College of Rheumatology 1997 revised criteria<sup>20,21</sup>. The diagnosis of SLE was confirmed by a rheumatologist after an in-depth face to face interview, medical history,

physical examination, chart review, and appropriate laboratory testing. To minimize bias associated with selection of controls from populations with intrinsically lower cigarette smoking rates or lower rates of SLE, demographically similar controls matched for sex and age (within 5 years) were randomly selected from the University of New Mexico general medicine outpatient clinics, using a computer list of patients who were seen in a one month period, and interviewed in person using the same questionnaire.

Regular smoking was defined as smoking at least one cigarette per day for at least 3 consecutive months. Subjects who had ever smoked cigarettes on a regular basis were asked these additional questions: age of onset of smoking, number of cigarettes or packs per day, current smoking status before the diagnosis of SLE, and age of quitting or stopping/restarting before the diagnosis of SLE, where applicable. Cases and controls were classified into 3 smoking status groups: (1) never smoker, (2) ex-smoker (defined by no smoking for one year prior to the diagnosis of SLE in SLE cases or prior to the pseudodiagnosis in the case of controls), (3) current smoker (defined by smoking at least one cigarette per day for at least 3 months prior to the reference date). Alcohol consumption (average drinks per week) over the past year was also recorded for both the SLE and control groups. The number of years of school completed (not completing high school/completion of high school/college or college graduate) and approximate household income over the past year were also collected.

**Statistical analysis.** Controls were assigned a "pseudodiagnosis" or "dummy" age, taken as the diagnosis age of the SLE case to which that control was matched since the smoking history referred to information preceding the diagnosis of SLE. Thus, for all cases and their matched controls, analysis of all data was restricted to the exposures noted before the diagnosis of SLE for cases and "pseudodiagnosis" for controls. Data were entered into a computerized spreadsheet (Excel, Version 5, Microsoft, Seattle, WA), and analyzed in SAS (SAS/STAT Software, Release 6.11, Cary, NC)<sup>22</sup>. Fisher's exact test was used to compare demographic and risk factor data between the SLE and control groups. The statistical significance of smoking and alcohol consumption as risk factors in the development of SLE, after adjusting for age, sex, ethnicity, family history of SLE, education level, and past income, was analyzed using multivariate conditional logistic regression. Stepwise regression was used for predictor variable selection, to obtain a "best" model, which was verified by "all subsets" regression.

## RESULTS

Characteristics of the cases and controls are shown in Table 1. Subject recruitment rates were similar, 91% for cases and 95% for controls. There was no overall difference between the SLE and control groups in regard to ethnicity, education, or income (all *p* values > 0.22). However, SLE patients revealed a markedly increased family history of SLE relative to the control group (*p* < 0.001).

The number of current smokers was 52 (41.6%) for the cases and 24 (19.2%) for the controls, a marked increase in cigarette smoking of all kinds in the SLE group (*p* < 0.001). All current smokers among the cases smoked at least one year prior to the diagnosis of SLE, and they smoked an average of 18 years prior to the diagnosis of SLE. The cigarette smoking and alcohol consumption distribution between the cases and controls are shown in Table 2.

Multivariate analysis of the data, using conditional logistic regression and adjusting for variables including age, ethnicity, alcohol consumption, family history, education, and income level led to a significant odds ratio (OR) for both current smokers and ex-smokers compared to never

Table 1. Demographic data of cases and controls.

	Cases	Controls	<i>p</i>
Total number of subjects	125	125	
Women	121	121	1.0
Men	4	4	
Mean age (yrs) at SLE diagnosis	36	36	1.0
IQR of age at diagnosis	25,46	25,47	
Mean current age, yrs	44	44	0.9
IQR of mean current age	34,55	34,55	
Mean duration of SLE	8.69		
Ethnic group			0.42
White	42	41	
Spanish American	80	74	
Black	1	5	
Asian	1	3	
Other	1	2	
Family history of SLE			< 0.001
Positive	33	2	
Negative	92	123	
Education			0.22
Never completed high school	27	39	
Completed high school	51	46	
College or college graduate	47	40	
Income (US dollars)*			0.42
< 25,000	77	79	
25–50,000	31	25	
50–100,000	8	15	
> 100,000	5	4	

\* 4 cases and 2 controls refused to answer this question. IQR: interquartile range.

Table 2. Distribution of cigarette smoking and alcohol consumption of SLE cases and controls.

	Cases	Controls	<i>p</i> **
Smoking status*			
Never smoker (%)	48 (38.4)	85 (68)	< 0.001
Ex-smoker (%)	25 (20)	16 (12.8)	
Current (%)	52 (41.6)	24 (19.2)	
No. of drinks/week***			0.08
0 (%)	93 (74.4)	105 (84)	
1–2 (%)	25 (20)	11 (8.8)	
3–5 (%)	5 (4)	6 (4.8)	
> 6 (%)	2 (1.6)	3 (2.4)	

\* Smoking status refers to the period prior to the diagnosis of SLE. \*\* Analysis by Fisher's exact test. \*\*\* Based on the average number of drinks over the past year.

smokers. Using stepwise regression, the best model used family history, past education, and smoking as variables. The adjusted OR for current and ex-smokers are shown in Table 3. As can be seen, cigarette smoking at the time of SLE diagnosis and ex-smoking significantly increased the risk of development of SLE [OR 6.69, 95% confidence intervals (CI) 2.59, 17.28, *p* < 0.001; and OR 3.62, 95% CI 1.22, 10.70, *p* = 0.02, respectively]. Family history does not

Table 3. Odds ratios (OR) of SLE for smoking status.

	OR**	95% CI	p
Smoking status*			
Never (%)	1.00	Not applicable	Not applicable
Ex-smoker	3.62	1.22, 10.70	0.02
Current smoker	6.69	2.59, 17.28	< 0.001

\* Smoking status refers to the period prior to the diagnosis of SLE.

\*\* Adjusted for family history and education.

alter the effect of smoking on SLE. Dichotomizing the pack-year variable according to whether a subject had smoked at least 10 pack-years or not (restricting the analysis to current and ex-smokers) showed there was no significant difference among pack-years smoked and SLE (OR 1.05, 95% CI 0.33, 3.31,  $p = 0.93$ ). There were no significant associations (positive or negative) between alcohol consumption and SLE (OR 0.7,  $p > 0.5$ ), and no significant interactions between alcohol consumption and smoking on SLE ( $p > 0.5$ ).

## DISCUSSION

The results of this study provide further evidence for smoking as an important risk factor for the development of SLE, and this is the first study showing an association between SLE and smoking in a predominantly Hispanic group. The results show that both current and ex-smokers before the diagnosis of SLE are at higher risk of developing SLE compared to never smokers. Nagata, *et al*, using a different patient population, also found that current cigarette smokers had a significantly increased risk of SLE (OR 2.31, 95% CI 1.34–3.97)<sup>16</sup>. The same study found that current smokers who smoked more than 20 pack-years had a significantly increased risk of SLE (OR 4.17, 95% CI 1.09–16.03). Hardy, *et al* also found that current smokers had a significantly increased risk of SLE (OR 1.95, 95% CI 1.14–3.31)<sup>17</sup>. McAlindon, *et al* in the Black Women's Health Study showed that both current and prior smoking were associated with SLE (OR 1.5, 95% CI 1.0–2.1)<sup>18</sup>. Many other epidemiological studies have found a positive association between smoking and other autoimmune conditions<sup>23–31</sup>. For example, cigarette smoking has been associated with rheumatoid arthritis, autoantibodies, Raynaud's phenomenon, Goodpasture's syndrome, Graves' disease, and severity of autoimmune disease<sup>32,33</sup>.

It is not surprising that cigarettes might have some effect on autoimmunity, as there are at least 55 chemical factors that affect cell growth or viability in cigarette smoke, including carbon monoxide, cyanide, hydrazine, hydroquinone, and others<sup>34–36</sup>. Certain of these chemicals are metabolized, which generate active species, including free radicals, which then can interact with DNA, cause mutations, activate tumor suppressor genes and oncogenes, and oxidatively damage nuclear constituents<sup>30,35–40</sup>. The indi-

vidual response to these chemical factors may have a strong genetic association that might contribute to SLE or lupus-like diseases<sup>41–44</sup>. Similarly, cigarette smoke enhances T and B cell polyclonal mitogenesis, expression of monocyte tissue factor, and production of immunomodulatory factors<sup>33,45</sup>.

It is also possible that cigarette smoking may act in concert with other environmental triggers, such as infection, to initiate the autoimmune process<sup>13</sup>. Since cigarette smoke has immunosuppressive qualities, cigarette induced immunosuppression might make the host more susceptible to the postulated infectious trigger of SLE<sup>13,43</sup>. However, the mechanisms by which cigarette smoking might enhance autoimmunity are still largely speculative, but may involve not just exposure, but the presence of an underlying predisposing genetic substrate that permits environmental induction of autoimmune processes<sup>46</sup>.

Case-control studies, although important epidemiological tools, have the potential for the observed associations to be affected by both systematic error and unsystematic error (random error). The statistics of our study make it very unlikely that the associations reported were a chance finding related to random error. However, systematic error could be introduced by bias associated with selection of patients and controls and measurement of smoking status. Bias associated with selection of patients was minimized by having the diagnosis of SLE confirmed by laboratory confirmation, by careful examination of the patient by a rheumatologist, and by the true cross sectional nature of the study, with very few patients in the SLE cohort refusing to participate.

The SLE group had a much higher prevalence of family history of SLE, consistent with the well known genetic predisposition to this disease. Nonetheless, the association of cigarette smoking remained even when controlling for the effects of family history and education, indicating that the association of cigarette smoking with SLE was a statistically independent effect.

To minimize the potential effects of bias in the selection of controls, we randomly selected controls from the same clinic area, resulting in a cohort that was very similar to the SLE cohort in age, sex, race, education, ethnic composition, and income (Table 1). Increased smoking in the SLE group could not be attributed to differences in any of these demographic factors. The percentage of female current smokers in New Mexico in 1998 was 20.2%, according to the US Department of Health and Human Services, Centers for Disease Control and Prevention<sup>47</sup>. The percentage of current smokers in our control population was 19.6%, thus making it representative of the New Mexico population.

It is also possible that the increased cigarette smoking was a psychoreactive behavior induced by the presence of subclinical disease that existed before the diagnosis of SLE. However, bias induced by psychoreactive use of cigarettes was minimized by defining smoking history before SLE

onset. Psychoreactive use of substances in these populations was also less likely because alcohol use between the 2 groups was similar, and increased use of both alcohol and tobacco might be expected if the change were a psychological reaction to underlying disease. Moreover, there was no association between alcohol use and SLE, which would have been expected if psychoreactive behavior were etiologic.

The experiment design, which employed self-reported data on smoking and alcohol, could potentially be associated with recall bias. The potential of recall bias was reduced, however, because previous and current smoking, stopping, and restarting were specifically investigated and recorded in the interview, and the interviewer was careful to be open, nonthreatening, and nonjudgmental in affect during collection of these data. Since smoking at the time of the interview was not a primary outcome variable, error could only be induced by misrepresentation of previous smoking, which has less basis for secondary gain than current smoking. Moreover, most investigators conclude that for assessment and epidemiological studies, self-reports of smoking status are sufficiently accurate to warrant their use<sup>48,49</sup>. In addition, one study reported that telephone interviews for smoking behavior might lead to a 3–4% underreport of smoking behavior, which would only make the association between smoking and SLE stronger<sup>50</sup>.

Recruitment/response rates also were excellent for this study, 91/100% for cases and 95/100% for controls, indicating that differences in recruitment and response were not likely sources of bias. The issue of temporality was addressed to some extent by the design of this study and the demonstration that both current smokers and past smokers before the diagnosis of SLE were at increased risk for the development of SLE, suggesting a “triggering” phenomenon in the induction of SLE, rather than a continuous induction relationship. A dose-response relationship (intensity and duration, in this case, pack-years of smoking) could not be observed, again suggesting a triggering phenomenon. Although reversibility was not specifically addressed in this study, all patients who had stopped cigarette smoking still had a markedly increased risk of developing SLE, again suggesting a triggering phenomenon. However, since the study design focused on the presence of disease and not on disease activity, reversibility was not fully addressed, although “reversibility” in SLE might have certain limitations related to preconceived concepts of SLE as a chronic, noncurable disease, as well as the definitional criteria used for formal diagnosis of SLE<sup>20,21</sup>.

Even allowing for the potential sources of bias discussed above, the data suggest strongly that current and ex-smokers are at a markedly increased risk for developing SLE. When the broader significance of this study is considered, the results suggest that people at increased risk for SLE (usually relatives of patients with SLE) should avoid

all contact with tobacco and its products. The present data also indicate that further studies regarding the specific role of tobacco smoke and associated chemical factors in the induction and modulation of autoimmunity are required.

## ACKNOWLEDGMENT

We thank Dr. Douglas Maple of the Epidemiology and Pulmonary Medicine Division and Dr. Richard Hoffman of the Internal Medicine Division for reviewing the study and providing valuable advice.

## REFERENCES

1. Hess EV, Farhey Y. Etiology, environmental relationships, epidemiology, and genetics of systemic lupus erythematosus. *Curr Opin Rheumatol* 1995;7:371-5.
2. Strom BL, Reidenberg MM, West S, Snyder ES, Freundlich B, Stolley PD. Shingles, allergies, family medical history, oral contraceptives, and other potential risk factors for systemic lupus erythematosus. *Am J Epidemiol* 1994;140:632-42.
3. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. *Ann Intern Med* 1995;122:430-3.
4. Theofilopoulos AN, Kono DH. The genes of systemic autoimmunity. *Proc Assoc Am Physicians* 1999;111:228-40.
5. Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. *Arthritis Rheum* 1997;40:804-8.
6. Pisetsky DS. Systemic lupus erythematosus: Epidemiology, pathology, and pathogenesis. In: Klippel JH, editor. *Primer on the rheumatic diseases*. 11th ed. Atlanta: Arthritis Foundation; 1997:246-50.
7. Davis P, Percy JS. Effect of ultraviolet light on disease characteristics of NZB/W mice. *Rheumatol* 1978;5:125-8.
8. Hahn BH. Pathogenesis of systemic lupus erythematosus. In: Kelley WN, editor. *Textbook of rheumatology*. 5th ed. Philadelphia: WB Saunders; 1997:1015-27.
9. Leslie RD, Hawa M. Twin studies in auto-immune disease. *Acta Genet Med Gemellol (Roma)* 1994;43:71-81.
10. Jarvinen P, Aho K. Twin studies in rheumatic diseases. *Semin Arthritis Rheum* 1994;24:19-28.
11. Maddison PJ. Nature and nurture in systemic lupus erythematosus. *Adv Exp Med Biol* 1999;455:7-13.
12. Tebbe B, Orfanos CE. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. *Lupus* 1997;6:96-104.
13. James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TJ, Harley JB. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. *J Clin Invest* 1997;100:3019-26.
14. Heimer H. Outer causes inner conflicts: environment and autoimmunity. *Environ Health Perspect* 1999;107:A504-9.
15. Reidenberg MM, Drayer DE, Lorenzo B, et al. Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. *Arthritis Rheum* 1993;36:971-3.
16. Nagata C, Fujita S, Iwata H, et al. SLE: A case controlled epidemiological study in Japan. *Int J Dermatol* 1995;34:333-7.
17. Hardy CJ, Palmer BP, Muir KR, Sutton AJ, Powell RJ. Smoking history, alcohol consumption, and systemic lupus erythematosus: a case controlled study. *Ann Rheum Dis* 1998;57:451-5.
18. McAlindon T, Felson D, Palmer J, Zheng L, Rosenberg L. Associations of cigarette smoking and alcohol with systemic lupus erythematosus among participants in the Black Women's Health Study [abstract]. *Arthritis Rheum* 1997;40 Suppl:S162.
19. Benoni A, Nilsson A, Nived O. Smoking and inflammatory bowel



- disease: Comparison with systemic lupus erythematosus: A case control study. *Scand J Gastroenterol* 1990;25:751-5.
20. Tan EM, Cohen AS, Fries JF, et al. 1982 Revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-7.
  21. Hochberg MC. Updating the ACR revised criteria for classification of SLE [letter]. *Arthritis Rheum* 1997;40:1725.
  22. SAS Institute Inc. SAS/STAT Software: changes and enhancements through Release 6.11. Cary, NC: SAS Institute Inc.; 1996:1104.
  23. Uhlig T, Hagen KB, Kvien TK. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. *J Rheumatol* 1999;26:47-54.
  24. Voight LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. *Epidemiology* 1994;5:525-32.
  25. Heliövaara M, Aho K, Aromaa A, Knekt P, Reunanen A. Smoking and risk of rheumatoid arthritis. *J Rheumatol* 1993;20:1830-5.
  26. Hazes JMW, Dijkman BAC, Vandenbroucke JP, de Vries RR, Cats P. Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption. *Ann Rheum Dis* 1990;49:980-2.
  27. Karlson EW, Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. *Arthritis Rheum* 1999;42:910-7.
  28. Saag KG, Cerhan JR, Kolluri S, Ohashi K, Hunninghake GW, Schwartz DA. Cigarette smoking and rheumatoid arthritis severity. *Ann Rheum Dis* 1997;56:463-9.
  29. Hernandez Avila M, Liang MH, Willett WC, et al. Reproductive factors, smoking, and the risk for rheumatoid arthritis. *Epidemiology* 1990;1:285-91.
  30. Finette BA, O'Neill JP, Vacek PM, Albertini RJ. Gene mutations with characteristic deletions in cord blood T lymphocyte associated with passive maternal exposure to tobacco smoke. *Nature Med* 1998;4:1144-51.
  31. Silman AJ, Newman J, MacGregor AJ. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. *Arthritis Rheum* 1996;39:732-5.
  32. Wallace DJ. Principles of therapy and local measures. In: Wallace DJ, Hahn BH, editors. *Dubois' lupus erythematosus*. 5th ed. Baltimore: Williams and Wilkins; 1997:1101.
  33. George J, Levy Y, Shoenfeld Y. Smoking and immunity: an additional player in the mosaic of autoimmunity. *Scand J Immunol* 1997;45:1-6.
  34. Mongey AB, Hess EV. The role of environment in SLE and associated disorders. In: Wallace DJ, Hahn BH, editors. *Dubois' lupus erythematosus*. 5th ed. Baltimore: Williams and Wilkins; 1997:31-2.
  35. Hecht SS. Tobacco smoke: carcinogens and lung cancer. *J Natl Cancer Inst* 1999;91:1194-210.
  36. Pyatt DW, Stillman WS, Irons RD. Hydroquinone, a reactive metabolite of benzene, inhibits NF-kappa B in primary human CD4+ T lymphocytes. *Toxicol Appl Pharmacol* 1998;149:178-84.
  37. McKinnon RA, Nebert DW. Possible role of cytochromes P450 in lupus erythematosus and related disorders. *Lupus* 1994;3:473-8.
  38. Yang Q, Hergenroth M, Bartsch H. Epstein-Barr virus episomes as targets for cigarette smoke- and gamma-irradiation-induced DNA damage: studies on the EBNA-1 region by a new gene-specific technique. *Carcinogenesis* 1997;18:1401-5.
  39. Muller T. Expression of c-fos in quiescent Swiss 3T3 cells exposed to aqueous cigarette smoke fractions. *Cancer Res* 1995;55:1927-32.
  40. Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T. Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. *Cell Immunol* 1999;192:48-53.
  41. Hirvonen A. Genetic factors in individual responses to environmental exposures. *J Occup Environ Med* 1995;37:37-43.
  42. Reidenberg MM, Durant PJ, Harris RA, De Boccardo G, Lahita R, Stenzel KH. Lupus erythematosus-like disease due to hydrazine. *Am J Med* 1983;75:365-9.
  43. Spector TD, Blake DR. Effect of cigarette smoking on Langerhans' cells. *Lancet* 1988;2:1028-9.
  44. Scofield RH, James J. Immunization as a model for systemic lupus erythematosus. *Arthritis Rheum* 1999;29:140-7.
  45. Holschermann H, Terhalle HM, Zakel U, et al. Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptives. *Thromb Haemost* 1999;82:1614-20.
  46. Cooper GS, Miller FW, Pandey JP. The role of genetic factors in autoimmune disease: implications for environmental research. *Environ Health Perspect* 1999;107 Suppl 5:693-700.
  47. Morgan KO, Morgan S. *Health care state rankings 2000*. 8th ed. Kansas: Morgan Quitno Corporation; 2000:504.
  48. Klesges RC, Debon M, Ray JW. Are self-reports of smoking rate biased? Evidence from the Second National Health and Nutrition Examination Survey. *J Clin Epidemiol* 1995;48:1225-33.
  49. Petitti DB, Friedman GD, Kahn W. Accuracy of information on smoking habits provided on self-administered research questionnaires. *Am J Public Health* 1981;71:308-11.
  50. Luepker RV, Pallonen UE, Murray DM, Pirie PL. Validity of telephone surveys in assessing cigarette smoking in young adults. *Am J Public Health* 1989;79:202-4.